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Abstract
Purpose—Studies of vitamin D pathway genetic variants in relation to cancer risk have been 
inconsistent. We examined associations between vitamin D-related genetic polymorphisms, 
plasma 25-hydroxyvitamin D [25(OH)D], and breast cancer risk.
Methods—In a population-based case-control study of 967 incident breast cancer cases and 993 
controls, we genotyped 25 polymorphisms encoding the vitamin D receptor (VDR) gene, 1α-
hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1), and vitamin D binding protein (GC) and 
measured plasma 25(OH)D. We used multivariable logistic regression to estimate adjusted odds 
ratios (ORs) and 95% confidence intervals (CI).
Results—Among CYP24A1 polymorphisms, rs6068816 was associated with a 72% reduction in 
breast cancer risk (TT vs. CC, OR: 0.28, 95%CI: 0.10–0.76; ptrend=0.01), but for rs13038432, the 
46% decrease included the null value (GG vs. AA, OR: 0.54, 95%CI: 0.17–1.67; ptrend=0.03). 
Increased risk that included the null value was noted for CYP24A1 rs3787557 (CC vs. TT, OR: 
1.34, 95% CI: 0.92–1.89). The VDR polymorphism, TaqI (rs731236), was associated with a 26% 
risk reduction (TT vs. CC, OR: 0.74, 95%CI: 0.56–0.98; ptrend=0.01). For other polymorphisms, 
ORs were weak and included the null value. The inverse association for plasma 25(OH)D with 
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breast cancer was more pronounced (OR: 0.43, 95%CI: 0.27–0.68) among women with the 
common allele for CYP24A, rs927650 (p for interaction on a multiplicative scale=0.01).
Conclusion—Breast cancer risk may be associated with specific vitamin D-related 
polymorphisms, particularly CYP24A1. Genetic variation in the vitamin D pathway should be 
considered when designing potential intervention strategies with vitamin D supplementation.
Keywords
breast cancer; vitamin D related gene polymorphisms; plasma 25-hydroxyvitamin D; CYP24A1
Introduction
Vitamin D in the body comes from two main sources, endogenous production from sun 
exposure (accounting for up to 90%) or ingestion of food or supplements [1]. Epidemiologic 
studies have consistently reported reduced breast cancer incidence and mortality associated 
with greater exposure to sunlight and ultraviolet B (UVB) irradiation [2–11]. However, 
results for studies evaluating dietary and supplemental intake of vitamin D and breast cancer 
risk are mixed [12–18]. Circulating 25-hydroxyvitamin D [25(OH)D] is an objective 
measure of vitamin D status from sunlight exposure, dietary, or supplement intake. Two 
recent meta-analysis of prospective studies showed overall 25(OH)D blood levels are 
associated with reduced breast cancer risk [19,20]. However, three recent prospective 
studies observed no association between 25(OH)D levels and breast cancer risk [21–23] and 
only one recent prospective study found an inverse association among whites, but not other 
ethnic groups [24].
Several enzymatic steps are involved in vitamin D metabolism. Genetic variants involved in 
vitamin D metabolism potentially modify cancer risk [25]. UVB exposure converts 7-
dehydrocholesterol into vitamin D3 (cholecalciferol). Metabolism is initiated when vitamin 
D3 is hydroxylated in the liver to 25(OH)D through a reaction catalyzed by 25-hydroxylase 
enzyme. If calcium levels drop, parathyroid hormone (PTH) is released and activates 1α-
hydroxylase (encoded by CYP27B1) that hydroxylates 25(OH)D to the active metabolite, 
1α,25-dihydroxyvitamin D [1,25(OH)2D]. 1,25(OH)2D binds to the vitamin D receptor 
(VDR), a ligand-dependent transcription factor, that regulates transcription of a number of 
genes involved in cell proliferation, differentiation, apoptosis, growth factor signaling, and 
immunomodulation [25,26]. Both 25(OH)D and 1,25(OH)2D can also be degraded into less 
active forms by 24-hydroxylase (encoded by CYP24A1). The group-specific component 
(GC) gene encodes the vitamin D-binding protein (DBP), which facilitates the transport of 
vitamin D metabolites.
Vitamin D pathway genetic polymorphisms may influence breast cancer risk. Most well-
studied are vitamin D receptor (VDR) polymorphisms. A comprehensive review found no 
evidence of a consistent association between VDR polymorphisms and breast cancer risk 
[27]. Studies of single nucleotide polymorphisms (SNPs) in GC found no significant 
association with breast cancer risk [25,28,29]. CYP27B1 and CYP24A1 are involved in the 
activation and degradation of 25(OH)D and 1,25(OH)2D. Only five studies examined the 
association between SNPs on these genes and breast cancer risk [25,28–31]. A review 
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suggests that some SNPs on these genes may be associated with breast cancer risk, but 
results are inconclusive [32].
Variations in these genes may influence vitamin D synthesis and levels of circulating 
vitamin D. Potential interactions between genotypes and vitamin D levels have not been 
adequately addressed in epidemiologic studies. Only three previous studies examined 
interactions between circulating 25(OH)D and VDR gene polymorphisms, specifically those 
detected by digestion with BsmI (rs1544410) and FokI (rs10735810) [33–35]. Effect 
modification of GC polymorphisms, CYP27B1 and CYP24A1, may also be important to 
breast cancer development. Less is known about these vitamin D-related genes and their 
association with breast cancer risk and interaction with circulating 25(OH)D.
Among participants in a population-based case-control study, the Long Island Breast Cancer 
Study Project (LIBCSP), we previously observed an inverse association between circulating 
25(OH)D and breast cancer risk [36]. Our objective here was to examine whether 
polymorphisms in genes involved in the vitamin D pathway may modify the association 
between 25(OH)D and breast cancer in an effort to identify susceptible subgroups of the 
population who may be at highest risk or who may benefit most from vitamin D exposure.
Materials and Methods
This study utilizes the LIBCSP, a population-based case-control study conducted on Long 
Island, New York [37]. Full details have been reported previously [37]. Institutional Review 
Board approval was obtained from all participating institutions.
Study Population
Breast cancer cases were women 20 years of age or older, residents of Nassau or Suffolk 
County, English-speaking, and newly diagnosed with in situ or invasive breast cancer 
between August 1, 1996 and July 31, 1997. Eligible cases were identified through daily or 
weekly contact with the 28 hospitals in these two counties, and three hospitals in New York 
City that treat Long Island residents diagnosed with breast cancer. Controls were women 
without breast cancer identified by random digit dialing for women under 65 years of age 
and through Health Care Finance Administration (now the Center for Medicare and 
Medicaid Services) rosters for women 65 years or older. Controls were frequency matched 
to the expected age distribution of the cases by 5-year age groups.
Trained interviewers administered the structured two-hour case-control questionnaire where 
respondents were asked about breast cancer risk factors and demographic characteristics 
[37]. In-person interviews were completed by 82.1% (n=1,508) of the eligible cases and 
62.7% (1,556) of the eligible controls. Respondents ranged in age from 20 to 98 years, were 
primarily postmenopausal (67%), and 93% self-reported as white, 5% black, and 2% other, 
which is consistent with the underlying racial distribution of the study area at the time of 
data collection [37].
Medical records of cases were abstracted to obtain information on tumor characteristics of 
the first primary breast cancer. Non-fasting blood samples were obtained at the time of the 
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interview from 73.1% of the case and 73.3% of the control respondents (n=1102 and 1141, 
respectively). Samples were collected prior to chemotherapy for 77.2% (851/1102) of the 
case respondents [37]. Plasma 25(OH)D measurements are absent in 6.9% of cases and 
5.8% of controls, due to insufficient sample to complete the assay [36].
We limited the study reported here to white women due to population stratification 
concerns, and thus our final sample size was 967 breast cancer cases and 993 controls. 
LIBCSP case and control participants who reported their race as white and with both DNA 
and serum available for this study had a mean age of 58.6 and 56.5 years, respectively [36]. 
Cases more often reported nulliplarity, a first-degree family history of breast cancer and 
history of benign breast disease. Season of blood draw was also slightly different between 
cases and controls. Cases had higher percentage of women with blood drawn in October to 
December as compared to controls (31.5% vs. 27.8%, respectively). However, controls had 
higher percentage of blood drawn in January to March as compared to cases (24.5% vs. 
18.2%, respectively). For the remaining months, April to September the frequency of blood 
draws was similar between cases and controls.
Measurement of Plasma 25(OH)D
Quantification of 25(OH)D in plasma was done via Diasorin radioimmunoassay (RIA) 
method. Prior to measurement, plasma samples were stored at −80°C. Samples were 
analyzed in batches between September and December 2007 using eight lots of the assay, as 
described previously [36]. Quality controls were utilized to assess inter-assay accuracy and 
precision. During each run quality control (QC) samples (n=5) were run together with the 
study samples. QC samples (n=2; 17.3 and 50.4 ng/mL) provided by Diasorin, pooled 
plasma sample (n=1; 23.6 ng/mL) and commercially available external QC samples (n=2; 
63.9 and 107.9 ng/mL). The inter-assay precision, determined for each QC from n=56 runs 
was 14.2, 15.7, 16.4, 14.2 and 5.7%, respectively. In addition, the lab successfully ran 
external proficiency samples from the UK-based vitamin D proficiency program DEQAS. 
Measurement of plasma 25(OH)D were performed in the laboratory of Dr. Serge Cremers at 
Columbia University Medical Center (CUMC).
Genotyping Assays
We selected 35 SNPs for genotyping with known or suspected impact on the vitamin D 
pathway or that had been associated with breast cancer in previous studies [27,32]. They 
included 20 SNPs in VDR: rs6823, BsmI (rs1544410), rs2071358, rs2107301, rs2239181, 
rs2239182, rs2408876, rs2544038, rs3782905, rs4073729, rs4760674, rs7299460, TaqI 
(rs731236), rs739837, rs7974708, ApaI (rs7975232), FokI (rs10735810), rs10875694, 
rs11168287, and rs11168314; 12 SNPs from 24-hydroxylase (CYP24A1): rs927650, 
rs2181874, rs2296241, rs2244719, rs2245153, rs2585428, rs2762939, rs3787557, 
rs4809960, rs6022999, rs6068816, and rs13038432; two from the vitamin D-binding protein 
(GC): rs4588 and rs7041; and one from 1α-hydroxylase (CYP27B1): rs4646537.
As previously described, genomic DNA was extracted from mononuclear cells in whole 
blood separated by Ficoll (Sigma Chemical Co., St. Louis, MO) and washed twice with 
phosphate-buffered saline [37]. Pelleted cells were frozen at −80°C until DNA isolation by 
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standard phenol and chloroform/isoamyl alcohol extraction. Master DNA 96-well plates 
containing 10 ng/μl were used to make replica plates. Genotyping of the SNPs was 
performed by the fluorogenic 5′-nuclease or TaqMan assay, using the TaqMan Core Reagent 
Kit (Applied Biosystems, Foster City, California). Polymerase chain reactions were carried 
out by using standard conditions recommended by the manufacturer. The fluorescence 
profile of each well was measured in an ABI 7500HT Sequence Detection System and the 
results analyzed with Sequence Detection Software (Applied Biosystems). Controls for 
genotype at each locus and two no DNA controls were included on each plate. Any samples 
that were outside the parameters defined by the controls were identified as non-informative 
and were retested. Four SNPs VDR (rs2239182, rs2239181), CYP24A1 (rs6068816) had 
concordance >98%. Most other SNPs fell between 95–98%, except four SNPs with 
concordance below 95% (rs2107301 and rs6823 had 94%, rs4760674 91% and rs4073729 
85% concordance) [38]. All SNPS had a call rate of 95% or better, except four: VDR 
(rs1544410: 89.1%; rs3782905 93.0%), CYP24A1 (rs2762939: 93.3%), and GC (rs7041: 
94.6%). Laboratory personnel were blinded to case/control status. Genotyping assays were 
performed in the laboratory of Dr. Regina Santella at CUMC.
Statistical Methods
For each of the 35 polymorphisms assayed, white subjects were divided into three groups 
based on genotype. We tested for deviation from Hardy-Weinberg equilibrium (HWE) 
among controls for each polymorphism using observed genotype frequencies and a χ2 test 
with one degree of freedom [39]. VDR (FokI, rs10735810) had significant departure from 
HWE and CYP27B1 (rs464537) had a minor allele frequency (MAF) of <5%; thus, both 
SNPs were excluded. We also excluded the four SNPs with concordance below 95%. The 
following ten SNPs were in linkage disequilibrium: VDR ApaI (rs7975232) and VDR 
rs739837; VDR BsmI (rs1544410) and VDR TaqI (rs731236); VDR rs3782905 and VDR 
rs7974708; CYP24A1 rs2585428 and CYP24A1 rs2296241; CYP24A1 rs4809960 and 
CYP24A1 rs2245153. Given the relative importance of BsmI and TaqI in other published 
literature, we elected to include these SNPs. We used ApaI instead of rs739837 as previous 
studies have suggested an association between ApaI and breast cancer, whereas rs739837 
has only been associated with fair skin and melanoma risk [40,41]. We selected rs3782905 
and rs4809960 instead of rs7974708 and rs2245153, respectively; due to previous studies 
suggesting an association with prostate cancer prognosis [42], whereas to our knowledge 
rs7974708 has not been investigated in relation to cancer. For the CYP24A1 SNPs, we 
selected rs2585428, instead of rs2296241, because a prior study found no association 
between breast cancer risk and rs2296241 [43]. Thus, the final number of SNPS included in 
our statistical analyses was 25.
Quantile regression was used to compare plasma 25(OH)D concentrations across all three 
genotypes and comparing a dominant model among controls [44]. We used log transformed 
plasma 25(OH)D concentrations, to normalize the distribution of 25(OH)D. To obtain 
plasma 25(OH)D concentrations that are adjusted for seasonal trend, we estimated the trend 
using a sine function among the controls, then we subtracted the estimated trend from 
measured plasma 25(OH)D. We used these adjusted values for all analyses that incorporated 
25(OH)D.
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We examined the association between genotype and breast cancer risk by unconditional 
logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) [45]. 
The genotype that was homozygous for the common allele was used as the referent category.
We conducted polytomous logistic regression for the association between genotype and 
subgroups of breast cancer defined by tumor characteristics [45]. ORs were estimated with 
cases classified by stage of disease (in situ vs. invasive) and hormone receptor status 
(estrogen receptor (ER)+ or progesterone receptor (PR)+ vs. ER−/PR− or ER+/PR+ vs. ER
−/PR−). The ratio of the ORs (ROR) was used as an indicator of etiological heterogeneity 
across disease stage and hormone receptor subtype [46].
Effect modification of plasma 25(OH)D across level of genotype was evaluated on a 
multiplicative scale comparing the likelihood ratio tests of logistic regression models with 
and without interaction terms [45]. Plasma 25(OH)D was divided into two categories (<19.1 
and ≥19.1 ng/mL), based on the lowest quartile of 25(OH)D vs. all above. Multiplicative 
interactions were assessed using indicator variables, where low plasma 25(OH)D (<19.1 
ng/mL) was the referent category in a dominant genetic model, stratified by homozygous 
common allele and heterozygous or homozygous minor allele.
We identified potential confounders using a directed acyclic graph (DAG): first degree 
family history of breast cancer, body mass index (BMI), oral contraceptive use, alcohol 
consumption, smoking, hormone replacement use, breastfeeding, and mammogram use. 
Potential confounders were included in the final models as a confounder if their inclusion 
significantly changed the log-likelihood of the model. Only two of these variables (family 
history of breast cancer and mammogram use) confounded the models. Therefore, all final 
statistical models include adjustment for age, first-degree family history of breast cancer, 
and mammogram use.
To aid in the interpretation of our results, we accounted for multiple comparisons using the 
Bonferroni correction [47]. Given we examined 25 SNPs, the corrected p-value denoting a 
significant association was p<0.002. All statistical analyses were conducted using SAS 
version 9.2 (SAS Institute, Cary, NC).
Results
Among white control women with DNA and serum samples available for this study, we 
found a difference in median plasma 25(OH)D concentrations across genotypes for several 
polymorphisms, as shown in Table 1. For almost half of control participants (44.9%), 
regardless of genotype, the geometric mean of plasma 25(OH)D was <30 ng/mL. For two 
VDR SNPs (rs2071358, rs2408876), we observed different geometric mean 25(OH)D levels 
across genotype. For the CYP27A1 (rs13038432), it appears that geometric mean plasma 
25(OH)D levels are lower among those with the GG genotype than those with AA genotype. 
For both GC polymorphisms (rs4588, rs7041), the lowest median plasma 25(OH)D was 
among those with homozygous minor alleles (p=0.001 and p=0.001, respectively).
As shown in Table 2, CYP24A1 rs6068816 was associated with a 72% reduction in breast 
cancer risk (TT vs. CC, OR: 0.28, 95% CI: 0.10–0.76, ptrend=0.01). Increased breast cancer 
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risk was noted for CYP24A1 rs6022999, rs2181874 and rs3787557, however the confidence 
intervals included the null value (GG vs. AA, OR: 1.35 95% CI: 0.95–1.90, ptrend=0.11; AA 
vs. GG, OR: 1.37, 95% CI: 0.96–1.95, ptrend=0.11; CC vs. TT, OR: 1.34, 95% CI: 0.92–
1.89, ptrend=0.49, respectively). For VDR polymorphisms, TaqI (rs731236), BsmI 
(rs1544410) and rs2544038 showed a decrease in odds of breast cancer (TT vs. CC, OR: 
0.74, 95% CI: 0.56–0.98, ptrend=0.01; GG vs. AA, OR: 0.74, 95% CI: 0.55–1.00, 
ptrend=0.03; TT vs. CC, OR: 0.74, 95% CI: 0.57–0.97, ptrend=0.03, respectively). For the 
remaining polymorphisms, associations with breast cancer were weak and confidence 
intervals included the null value. Once we adjusted for multiple comparisons, none of the 
SNP-breast cancer risk p-values were <0.002, the threshold determined using the Bonferroni 
correction.
As presented in Table 3, we observed little or no heterogeneity in the association between 
vitamin-D related SNPs and breast cancer across tumor characteristics of the first primary 
breast cancer, with a few exceptions. For VDR rs2408876, there was a 42% decreased breast 
cancer risk among patients either ER+ or PR+ tumors as compared to women with ER−/PR− 
tumors (ROR: 0.59, 95% CI: 0.36–0.98). We also examined heterogeneity between ER+/PR
− and ER−/PR− tumors and found similar variations in the RORs, with attenuation of most 
of the ORs (Supplemental Table 1). Other SNPs showed apparent variability across tumor 
subtypes, but the confidence intervals for the measure of heterogeneity included the null 
value.
We noted effect modification on a multiplicative scale (p≤0.05) for CYP24A1 polymorphism 
rs927650. Women homozygous for the common allele of CYP24A1 rs927650 who had 
plasma 25(OH)D of ≥ 19.1 ng/mL had reduced breast cancer risk compared to women with 
plasma 25(OH)D <19.1 ng/mL (OR: 0.43, 95% CI: 0.27–0.68; Supplemental Table 2). With 
adjustment for multiple comparisons, none of the interaction p-values were below the 
Bonferroni-determined threshold. Our findings however, were based on small numbers of 
women and therefore should be interpreted with caution. In analyses restricted to 
postmenopausal women the interaction for CYP24A1 (rs927650) was no longer significant 
(Supplemental Table 3).
Discussion
In this population-based case-control study, we observed reduced risks for breast cancer in 
association with select biologically plausible vitamin D-related gene polymorphisms, 
particularly CYP24A1. Specifically, we observed potential 72% and 46% reductions for 
breast cancer risk in association with the homozygous minor allele genotype for CYP24A1 
polymorphism rs6068816 and rs13038432. After accounting for multiple comparisons, 
however, we found no interactions between CYP24A1 and GC polymorphisms and plasma 
25(OH)D. To our knowledge, this is the first study to examine effect modification of breast 
cancer risk by plasma 25(OH)D among vitamin D-related gene polymorphisms other than 
VDR.
CYP24A1 is located on chromosome 20 (Figure 1b) and plays an important role in vitamin D 
metabolism, specifically regulating the level of active vitamin D [27]. CYP24A1 is amplified 
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in breast tumors, which may nullify growth control [48]. Two previous studies found no 
association between CYP24A1 polymorphisms (rs2296241, rs2181874, rs4809958 and 
rs601305) and breast cancer risk [25,28] and another study found an increased risk with one 
polymorphism (rs6091822) and a decreased risk with two other CYP24A1 polymorphisms 
(rs8124792 and rs6097809) [29]. We found decreased breast cancer risk for two CYP24A1 
polymorphisms that were not examined in these previous studies, rs13038432 and 
rs6068816.
In our study, there was a potential interaction between CYP24A1 polymorphism rs927650 
and plasma 25(OH)D; breast cancer risk was reduced among women with the homozygous 
common allele with plasma 25(OH)D ≥19.1 ng/mL compared to those with 25(OH)D <19.1 
ng/mL. A recent genome-wide association study (GWAS) demonstrated that variation in 
CYP24A1 was related to circulating levels of 25(OH)D [49]. CYP24A1 encodes 24-
hydroxylase, which degrades 1,25(OH)2D, reducing the growth control of 1,25(OH)2D and 
potentially increasing breast cancer risk among women with certain CYP24A1 
polymorphisms [27]. We did not test for rs6013897, which has been highlighted in a recent 
GWAS study [49] as associated with vitamin D insufficiency. To our knowledge no 
previous publication has examined linkage disequilibrium between rs6013897 and any 
CYP24A1 polymorphisms. Our findings appear to be compatible with the known function of 
CYP24A1, which suggests that the association with breast cancer may be modified through 
25(OH)D.
We also found potential breast cancer risk reductions for a number of VDR polymorphisms, 
including BsmI (rs1544410), TaqI (rs731236), and rs2544038. It is interesting to note, all the 
VDR polymorphisms associated with decreased breast cancer risk or plasma 25(OH)D in our 
study were closer to the 3′ end of the promoter region and part of block B (Figure 1a) [50]. 
The functionality of these VDR polymorphisms is not completely understood [51]. The TaqI 
(rs731236) polymorphism is on block B and part of the ligand-binding domain [27]. Our 
findings of a reduced risk comparing CC vs. TT in TaqI are consistent with the magnitude of 
effect observed in previous studies [52,35]. However, a few other studies have found an 
increased risk or no association, but these studies were composed of slightly different 
populations, either premenopausal women only or women in other countries with differing 
sun exposure [53,54]. Our findings of a reduced risk with BsmI are consistent with one 
previous study among white women [17], and two other studies [55,56] conducted within 
populations of different racial backgrounds. However, other studies conducted within white 
populations showed an increased breast cancer risk with BsmI [57,58,33,34,59]. We know of 
only one study that also assessed rs2544038, which found a slightly increased breast cancer 
risk with the CC vs. TT genotype [60].
Among VDR polymorphisms associated with increased risk, one SNP has not been 
previously published in relation to breast cancer, rs2239182. Our study showed ApaI was 
associated with an increased breast cancer risk, which is consistent with three previous 
studies [53,61,62] and inconsistent with three others [56,52,25]. It is unclear if ApaI is 
associated with increased breast cancer risk or if these are chance findings.
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Within the vitamin D-binding protein encoded by GC, we examined two relatively common 
SNPs, rs7041 and rs4588 (Figure 1c). Previous breast cancer studies have found varied 
results [25,28]. In our population, we observed weak increases in breast cancer risk, with 
confidence intervals that included the null value, for both of these polymorphisms. Our 
breast cancer risk estimates were similar for rs7041 to two recent studies [25,28] and similar 
in rs4588 to one of these studies [25]. However, two other studies found a decreased breast 
cancer risk for rs7041 [63,64], only one examined rs4588 and also found an inverse 
association [63]. For both rs7041 and rs4588, we observed some variation in plasma 
25(OH)D levels across genotype. Overall, our findings are in agreement with a recent study 
that showed GC variation is associated with 25(OH)D concentrations [65]. However, a 
GWAS study showed only GC rs2282679 was associated with vitamin D insufficiency, and 
thus variation in 25(OH)D across genotype may be influenced by other mechanisms [49].
These results support the concept that breast carcinogenesis may be influenced by the 
vitamin D axis, including the interaction between the different components of vitamin D, 
which includes circulating vitamin D, the VDR and the vitamin D-binding protein [66]. Few 
previous studies have assessed interactions between circulating 25(OH)D and vitamin D 
polymorphisms on breast cancer risk [33–35,63].
We acknowledge the following limitations of our study. First, we used a biologically based 
approach for SNP selection [67–69], however, with adjustments for multiple comparisons, 
none of the associations we observed met the conservative Bonferroni-threshold for 
significance. Thus, our results could be due to chance. Second, given that blood was 
collected near diagnosis and that 25(OH)D has a relatively short half-life of approximately 
2–3 weeks [70], circulating vitamin D levels at the time of diagnosis may not reflect the 
etiologically relevant window timeframe. Third, we limited our analyses to white women, 
given genotypes in VDR have been shown to vary by race and ethnicity [71]. This may limit 
generalizability of our findings; however, our homogenous population is also a study 
strength, because there is less genetic variability. Fourth, our results are based on a small 
number of case subjects with the homozygous minor allele. It is unclear if our findings 
would be replicated in a larger study with more women with the homozygous minor alleles 
in CYP24A1 gene.
Our study improves upon previous studies in a number of different ways. First, we examined 
a number of biologically plausible polymorphisms, not just those on VDR. Our results show 
that other vitamin D-related genes – particularly CYP24A1 - may also be important in 
understanding the relationship between vitamin D and breast cancer risk. Second, our study 
is based on incident breast cancer cases. Vitamin D levels can also be affected by treatment 
[72–74] and changes in lifestyles behaviors after diagnosis with breast cancer. Blood 
samples in our population were collected prior to treatment with chemotherapy in 70% of 
the cases. Third, our study was population-based, reducing the likelihood of unquantified 
selection biases that are inherent in using select populations. As previously reported [37], 
LIBCSP participants for whom blood samples were available were more likely to be 
younger, report their race as white, to ever use alcohol, ever used hormone replacement, 
breast fed for more than 6 months, ever had a mammogram, and less likely to be past 
smokers. However, all statistical analyses included the frequency matching factor age, were 
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limited to whites only, and adjusted for ever having a mammogram, which may have helped 
to limit some of the potential selection bias associated with these differences. In addition, 
alcohol use, hormone replacement use, breastfeeding, and smoking were not confounders in 
our analyses. Further, our incidence density sampling approach improves our ability for 
estimating rate ratios, which enhances interpretation of our findings.
In conclusion, in our population-based study, breast cancer risk was associated with specific 
vitamin D-related SNPs, supporting the biologic plausibility of a relationship between 
vitamin D and breast cancer risk. Prospective studies evaluating 25(OH)D and breast cancer 
risk have had mixed results, some studies found 25(OH)D decreases breast cancer risk 
[19,20,24], whereas others reported no association [21–23]. We observed that the inverse 
association with vitamin D may be stronger among women with polymorphisms within 
CYP24A1. Genetic variation in the vitamin D pathway, specifically in CYP24A1, is 
potentially important to breast cancer risk, which should be considered when designing 
potential intervention strategies with vitamin D supplementation.
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Refer to Web version on PubMed Central for supplementary material.
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Position of vitamin D related gene polymorphisms use for analysis within each gene, a) VDR 
gene block and exon structure, individual SNPs are indicated with an arrow, b) CYP24A1 
gene, and c) GC gene. Exons are indicated by a square with the exon number in the middle.
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